New 1, 3, 4‐oxadiazole‐chalcone/benzimidazole hybrids as potent antiproliferative agents. Issue 2 (9th November 2022)

• Record Type: Journal Article
• Authors: Hagar, Fatma Fouad; Abbas, Samar H.; Abdelhamid, Dalia; Gomaa, Hesham A. M.; Youssif, Bahaa G. M.; Abdel‐Aziz, Mohamed
• Is Part Of: Archiv der Pharmazie. Volume 356:Issue 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-09
• Subjects: antiproliferative -- benzimidazole -- BRAFV600E -- chalcone -- EGFR; Pharmaceutical chemistry -- Periodicals; Pharmacology -- Periodicals; 615.19
• DOI: 10.1002/ardp.202200357
• Languages: English
• ISSNs: 0365-6233

Abstract

Abstract: A series of new 1, 3, 4‐oxadiazole‐chalcone/benzimidazole hybrids 9a–o and 10a–k were designed and synthesized as potential antiproliferative agents. Hybrids 9a–o exhibited remarkable antiproliferative activities on different NCI‐60 cell lines in a single‐dose assay. The antiproliferative activities of the newly synthesized compounds were evaluated against a panel of four human cancer cell lines (A‐549, MCF‐7, Panc‐1, and HT‐29). Compounds 9g–i and their oxygen isosteres, 10f–h, exhibited promising antiproliferative activities with IC50 values ranging from 0.80 to 2.27 µM compared to doxorubicin (IC50 ranging from 0.90 to 1.41 µM). Furthermore, the inhibitory potency of these compounds against the epidermal growth factor receptor (EGFR) and BRAF V600E kinases was evaluated using erlotinib as a reference drug. Molecular modeling studies were done to investigate the binding mode of the most active hybrids in the ATP binding site of EGFR. Abstract : New 1, 3, 4‐oxadiazole‐chalcone/benzimidazole hybrids (9a–o and 10a–k ) were designed and synthesized as potential antiproliferative agents. Hybrids 9a–o exhibited remarkable antiproliferative activities on different cell lines in the NCI‐60 panel in a single‐dose assay. In particular, compounds 9g–i and their oxygen isosteres, 10f–h, exhibited promising antiproliferative activities on A‐549, MCF‐7, Panc‐1, and HT‐29 cells.